These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 34539621)

  • 41. Mammalian Target of Rapamycin Inhibitor Monotherapy: Efficacy in Renal Transplantation.
    Franco A; Más-Serrano P; Perez Contreras J; Jiménez L; Rodriguez D; Olivares J
    Transplant Proc; 2015 Oct; 47(8):2364-7. PubMed ID: 26518928
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunosuppressive agents for treating IgA nephropathy.
    Natale P; Palmer SC; Ruospo M; Saglimbene VM; Craig JC; Vecchio M; Samuels JA; Molony DA; Schena FP; Strippoli GF
    Cochrane Database Syst Rev; 2020 Mar; 3(3):CD003965. PubMed ID: 32162319
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of calcineurin inhibitor-free immunosuppression on de novo donor-specific antibody formation in liver transplant recipients.
    Meszaros M; Dubois V; Congy-Jolivet N; Hamada S; Thevenin C; Faure S; Boillot O; Kamar N; Pageaux GP; Del Bello A; Dumortier J
    Liver Int; 2022 May; 42(5):1132-1143. PubMed ID: 35184373
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effectiveness and safety of calcineurin inhibitor withdrawal in kidney transplantation: a meta-analysis of randomized controlled trials.
    Bai H; Qian Y; Shi B; Wang Z; Li G; Fan Y; Yuan M; Liu L
    Clin Exp Nephrol; 2015 Dec; 19(6):1189-98. PubMed ID: 25820574
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen.
    Chhabra D; Alvarado A; Dalal P; Leventhal J; Wang C; Sustento-Reodica N; Najafian N; Skaro A; Levitsky J; Mas V; Gallon L
    Am J Transplant; 2013 Nov; 13(11):2902-11. PubMed ID: 24007570
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS; Cho YW; Shah T; Bunnapradist S; Hutchinson IV
    Transplantation; 2012 Jan; 93(1):73-81. PubMed ID: 22129761
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Calcineurin and mTOR inhibitors in kidney transplantation: integrative metamodeling on transplant survival and kidney function.
    Khalid H; Fareed MM; Dandekar T; Shityakov S
    Int Urol Nephrol; 2024 Apr; 56(4):1403-1414. PubMed ID: 37751051
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of De Novo mTOR Inhibitors in Hypersensitized Kidney Transplant Recipients: Experience From Clinical Practice.
    Cucchiari D; Molina-Andujar A; Montagud-Marrahi E; Revuelta I; Rovira J; Ventura-Aguiar P; Piñeiro GJ; De Sousa-Amorim E; Esforzado N; Cofán F; Torregrosa JV; Ugalde-Altamirano J; Ricart MJ; Centellas-Pérez FJ; Solè M; Martorell J; Ríos J; Campistol JM; Diekmann F; Oppenheimer F
    Transplantation; 2020 Aug; 104(8):1686-1694. PubMed ID: 32732848
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conversion from calcineurin inhibitors to mTOR inhibitors as primary immunosuppressive drugs in pediatric heart transplantation.
    Asante-Korang A; Carapellucci J; Krasnopero D; Doyle A; Brown B; Amankwah E
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28708333
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-Term Renal Function in Liver Transplant Recipients After Conversion From Calcineurin Inhibitors to mTOR Inhibitors.
    Hüsing A; Schmidt M; Beckebaum S; Cicinnati VR; Koch R; Thölking G; Stella J; Heinzow H; Schmidt HH; Kabar I
    Ann Transplant; 2015 Nov; 20():707-13. PubMed ID: 26608590
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes of Conversion From Calcineurin Inhibitor to Belatacept-based Immunosuppression in HLA-sensitized Kidney Transplant Recipients.
    Sethi S; Najjar R; Peng A; Choi J; Lim K; Vo A; Jordan SC; Huang E
    Transplantation; 2020 Jul; 104(7):1500-1507. PubMed ID: 31568398
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cordyceps sinensis (a traditional Chinese medicine) for kidney transplant recipients.
    Hong T; Zhang M; Fan J
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD009698. PubMed ID: 26457607
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Belatacept rescue conversion in kidney transplant recipients with vascular lesions (Banff cv score >2):  a retrospective cohort study.
    Bertrand D; Matignon M; Morel A; Ludivine L; Lemoine M; Hanoy M; Roy FL; Nezam D; Hamzaoui M; de Nattes T; Moktefi A; François A; Laurent C; Etienne I; Guerrot D
    Nephrol Dial Transplant; 2023 Feb; 38(2):481-490. PubMed ID: 35544123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: A systematic review and meta-analysis.
    Zhang G; Duan B; Li G
    Clin Transplant; 2022 Dec; 36(12):e14823. PubMed ID: 36124430
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Everolimus in de novo liver transplant recipients: a systematic review.
    Tang CY; Shen A; Wei XF; Li QD; Liu R; Deng HJ; Wu YZ; Wu ZJ
    Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):461-9. PubMed ID: 26459721
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
    Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
    Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Treatment strategies in pediatric solid organ transplant recipients with calcineurin inhibitor-induced nephrotoxicity.
    Tönshoff B; Höcker B
    Pediatr Transplant; 2006 Sep; 10(6):721-9. PubMed ID: 16911497
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunosuppressive drug combinations after kidney transplantation and post-transplant diabetes: A systematic review and meta-analysis.
    Oliveras L; Coloma A; Lloberas N; Lino L; Favà A; Manonelles A; Codina S; Couceiro C; Melilli E; Sharif A; Hecking M; Guthoff M; Cruzado JM; Pascual J; Montero N
    Transplant Rev (Orlando); 2024 Jul; 38(3):100856. PubMed ID: 38723582
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Microvascular inflammation is a risk factor in kidney transplant recipients with very late conversion from calcineurin inhibitor-based regimens to belatacept.
    Choi M; Bachmann F; Wu K; Lachmann N; Schmidt D; Brakemeier S; Duerr M; Kahl A; Eckardt KU; Budde K; Nickel P
    BMC Nephrol; 2020 Aug; 21(1):354. PubMed ID: 32819287
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP; Pascoe MD; Alberu J; del Carmen Rial M; Oberbauer R; Brennan DC; Campistol JM; Racusen L; Polinsky MS; Goldberg-Alberts R; Li H; Scarola J; Neylan JF;
    Transplantation; 2009 Jan; 87(2):233-42. PubMed ID: 19155978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.